SSGJ-627 vs tulisokibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TL1A · full Ulcerative Colitis pipeline
SSGJ-627
Developed by Sunshine Guojian Pharmaceutical and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: February 2029 · NCT07507513 (registry estimate)
No aligned efficacy figure on record for this race.
tulisokibart
Developed by Merck & Co.
NCT06052059 · Phase 3 · active, not recruiting
First Ph3 induction win for any anti-TL1A; met primary + key secondaries (June 2026).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2037 · NCT06651281 (registry estimate)
Reported efficacy
Clinical remission (MMS) at week 12: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints. (met)
Result source: NCT06052059
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | SSGJ-627 | tulisokibart |
|---|---|---|
| Clinical remission (induction) | —Not reported | 26.5% vs 1.5%+25 vs placeboNCT049967971 other result
|
| Clinical remission (maintenance) | —Not reported | —Trial running · NCT06052059 |
| Clinical response (induction) | —Not reported | 66.2% vs 22.4%+43.8 vs placeboNCT049967971 other result
|
| Endoscopic improvement (induction) | —Not reported | 36.8% vs 6%+30.8 vs placeboNCT049967971 other result
|
| Corticosteroid-free remission (maintenance) | —Not reported | —Trial running · NCT06052059 |
Clinical remission (induction)
- SSGJ-627
- —Not reported
- tulisokibart
- 26.5% vs 1.5%+25 vs placeboNCT04996797
1 other result
- 31.6% vs 10.8% NCT04996797
Clinical remission (maintenance)
- SSGJ-627
- —Not reported
- tulisokibart
- —Trial running · NCT06052059
Clinical response (induction)
- SSGJ-627
- —Not reported
- tulisokibart
- 66.2% vs 22.4%+43.8 vs placeboNCT04996797
1 other result
- 55.3% vs 32.4% NCT04996797
Endoscopic improvement (induction)
- SSGJ-627
- —Not reported
- tulisokibart
- 36.8% vs 6%+30.8 vs placeboNCT04996797
1 other result
- 36.8% vs 18.9% NCT04996797
Corticosteroid-free remission (maintenance)
- SSGJ-627
- —Not reported
- tulisokibart
- —Trial running · NCT06052059
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
SSGJ-627: no structured comparison results are available for Ulcerative Colitis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. SSGJ-627: 0 of 4 rows · tulisokibart: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | tulisokibart |
|---|---|
| Dropout rate | —All Cohorts (Cohort 1 & Cohort 2) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 show 1 more resultn/a: no completion milestoneCohort 1 Tulisokibart NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Discontinued due to AEs | —All Cohorts (Cohort 1 & Cohort 2) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 show 1 more result0%Cohort 1 Tulisokibart NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Serious AEs | 1.1%All Cohorts (Cohort 1 & Cohort 2) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 show 1 more result—Cohort 1 Tulisokibart NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Most frequent reported AEs | covid-19 5.6% (placebo 4.5%) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 |
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
tulisokibart
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SSGJ-627's landscape · tulisokibart's landscape